What is the recommended treatment summary for a hypertensive emergency?

Treatment Summary for Hypertensive Emergency

Critical First Step: Distinguish Emergency from Urgency

The presence or absence of acute target-organ damage—not the absolute blood pressure value—determines whether immediate IV therapy is required. 1, 2, 3

• Hypertensive emergency = BP >180/120 mmHg WITH acute organ damage (encephalopathy, stroke, MI, pulmonary edema, aortic dissection, acute renal failure, retinal hemorrhages/papilledema) → requires ICU admission and IV therapy 1, 2, 3
• Hypertensive urgency = BP >180/120 mmHg WITHOUT acute organ damage → managed with oral agents and outpatient follow-up; IV therapy is contraindicated 1, 2, 3

Rapid Bedside Assessment for Target-Organ Damage

• Neurologic: altered mental status, severe headache with vomiting, visual changes, seizures, focal deficits 2
• Cardiac: chest pain, pulmonary edema, acute heart failure 2
• Ophthalmic: fundoscopy for bilateral retinal hemorrhages, cotton-wool exudates, papilledema (malignant hypertension) 1, 2
• Renal: acute creatinine rise, oliguria, new proteinuria 2
• Vascular: sudden chest/back pain suggesting aortic dissection 2

---

Management of Hypertensive Emergency (With Acute Organ Damage)

Immediate Actions

Admit to ICU with continuous arterial-line blood pressure monitoring (Class I recommendation). 1, 2, 3

Blood Pressure Reduction Targets

Reduce mean arterial pressure by 20–25% (maximum) within the first hour, then target <160/100 mmHg over the next 2–6 hours if stable, and cautiously normalize over 24–48 hours. 1, 2, 3

• Critical safety threshold: Avoid systolic drops >70 mmHg to prevent cerebral, renal, or coronary ischemia, especially in chronic hypertensives with altered autoregulation 1, 2, 3

First-Line Intravenous Agents

Drug	Preferred Indication	Dosing	Key Advantages	Contraindications
Nicardipine	Most emergencies except acute heart failure	Start 5 mg/h IV; increase by 2.5 mg/h every 5–15 min; max 15 mg/h	Preserves cerebral blood flow, predictable titration, does not raise ICP	Acute heart failure (may cause reflex tachycardia) [1,2,4]
Labetalol	Aortic dissection, eclampsia, hypertensive encephalopathy	0.25–0.5 mg/kg IV bolus or 2–4 mg/min infusion; max 300 mg cumulative	Combined α/β-blockade, leaves cerebral blood flow intact	Asthma, COPD, heart block, bradycardia, decompensated heart failure [1,2,3]
Clevidipine	Situations requiring very rapid titration	Start 1–2 mg/h; double every 90 sec; max 32 mg/h	Ultra-short onset/offset (5–15 min), easy titration	Soy or egg allergy [1,2]

---

Scenario-Specific Targets and Agents

Acute Aortic Dissection

• Target: Systolic <120 mmHg and heart rate <60 bpm within 20 minutes 1, 2
• Agent: Beta-blocker FIRST (esmolol or labetalol) to prevent reflex tachycardia, then add nicardipine or nitroprusside 1, 2
• Pitfall: Never use nicardipine alone—reflex tachycardia worsens shear stress 1, 4

Acute Ischemic Stroke

• Pre-thrombolytic: Maintain BP <185/110 mmHg before rtPA 1, 2, 4
• Post-thrombolytic: Maintain BP <180–185/<105–110 mmHg 1, 2, 4
• General ischemic stroke (no thrombolysis): Only lower BP if >220/120 mmHg; reduce MAP by 15% in first 24 hours 1
• Agent: Labetalol preferred; nicardipine or nitroprusside alternatives 1
• Pitfall: Acute BP reduction within first 5–7 days is associated with adverse neurological outcomes 1

Acute Hemorrhagic Stroke

• Target: Systolic 130–180 mmHg (intensive lowering to <140 mmHg reduces hematoma volume) 1, 2
• Agent: Labetalol, nicardipine, or nitroprusside 1

Hypertensive Encephalopathy

• Agent: Labetalol preferred (does not increase ICP); nicardipine or nitroprusside alternatives 1

Acute Coronary Syndrome

• Target: Systolic <140 mmHg 1, 2
• Agent: Nitroglycerin first-line; labetalol if tachycardia present 1
• Avoid: Nitroprusside (decreases regional coronary flow and increases myocardial damage) 1

Acute Cardiogenic Pulmonary Edema

• Agent: Nitroprusside (optimizes pre- and afterload) or nitroglycerin 1
• Avoid: Nicardipine (may cause reflex tachycardia) 1, 4

Eclampsia/Preeclampsia

• Target: Systolic <140 mmHg within first hour 1, 2
• Agents: Hydralazine, labetalol, or nicardipine 1, 2, 4

Acute Renal Failure

• Agents: Clevidipine, fenoldopam, or nicardipine (preserve renal perfusion) 2, 4

Cocaine/Amphetamine Intoxication

• First-line: Benzodiazepines 1, 2
• If additional BP lowering needed: Phentolamine, nicardipine, or nitroprusside 1, 2
• Avoid: Beta-blockers (unopposed alpha stimulation) 1

---

Management of Hypertensive Urgency (No Acute Organ Damage)

IV antihypertensives are contraindicated—oral therapy with outpatient follow-up is the standard of care. 1, 2, 3

Blood Pressure Reduction Goals

• First 24–48 hours: Gradual reduction to <160/100 mmHg 1, 2
• Subsequent weeks: Target <130/80 mmHg 2
• Pitfall: Rapid reductions precipitate cerebral, renal, or coronary ischemia in chronic hypertensives 1, 2

Preferred Oral Agents

• Captopril 12.5–25 mg PO (start low due to volume depletion from pressure natriuresis) 1, 2
• Extended-release nifedipine 30–60 mg PO 1, 2
• Oral labetalol 200–400 mg PO 1, 2
• NEVER use immediate-release nifedipine (unpredictable precipitous drops cause stroke and death) 1, 2

Observation and Follow-Up

• Observe for at least 2 hours after medication to confirm efficacy and safety 1, 2
• Schedule outpatient visit within 2–4 weeks, then monthly until target BP achieved 1, 2

---

Critical Pitfalls to Avoid

• Do not treat asymptomatic severe hypertension as an emergency—most cases are urgency, and aggressive IV therapy causes more harm than benefit 1, 2, 5
• Do not lower BP by >25% in the first hour or allow systolic drops >70 mmHg—precipitates stroke, MI, or acute kidney injury 1, 2, 3
• Do not use IV agents for hypertensive urgency—oral therapy is safer and guideline-recommended 1, 2, 3
• Do not use immediate-release nifedipine—associated with stroke and death 1, 2
• Do not use nitroprusside for >48–72 hours—risk of cyanide toxicity 1, 3
• Do not use nicardipine alone in aortic dissection—beta-blockade must come first 1, 4

---

Post-Stabilization Considerations

• Transition to oral antihypertensives as soon as possible to minimize IV therapy duration 1, 3
• Screen for secondary causes (renal artery stenosis, pheochromocytoma, primary aldosteronism)—identified in 20–40% of malignant hypertension cases 2
• Address medication non-adherence—the most common trigger for hypertensive emergencies 1, 2
• Long-term BP control is paramount—untreated hypertensive emergencies carry >79% one-year mortality 2